The Week

Johnson & Johnson (JNJ) added 1.66% this week to close at $269.99, outperforming the S&P 500 by about 1.74 percentage points while the benchmark slipped 0.08%. The week was not a straight line: shares opened higher on Monday before fading to $266.32, touched an intraday low of $260.68 on Tuesday, then recovered over the following three sessions. Friday saw heavier volume as the stock pushed to a weekly high of $272.11 and settled near the top of the range. Weekly amplitude came to 4.22%, and average daily volume of 7.58 million shares ran about 12% above the 60-day median.

Key Events

The narrative this week centred on JNJ’s oncology pipeline and a potential restructuring move. Early in the week, around the World Conference on Lung Cancer 2026, the company highlighted RYBREVANT data in EGFR exon 20 insertion-mutant non-small cell lung cancer, including the longest reported median overall survival with chemotherapy and low treatment-related event rates for RYBREVANT FASPRO plus LAZCLUZE. On Tuesday, partner Contineum reported that JNJ-5120/PIPE-307 missed its primary endpoint in the Phase 2 MOONLIGHT-1 depression trial, sending Contineum shares down about 10% after hours and weighing on sentiment. From midweek, reports said Apollo was in talks to acquire JNJ’s DePuy Synthes orthopaedics unit in a deal worth roughly $20 billion. On Friday, EU regulators signalled a CHMP recommendation to approve TECVAYLI, adding another regulatory step for the multiple myeloma pipeline.

Analyst Ratings

Across 24 covering firms, 11 rate JNJ a buy, 5 overweight, 6 hold, 1 underweight and 1 sell, with 1 offering no opinion; buy and overweight together total 16. The consensus rating is buy, and the consensus target price sits at $277.91, about 2.93% above the latest close. Targets range from a low of $190 to a high of $320, a spread of more than 68%, pointing to unusually wide disagreement. The stock ranks fifth by analyst rating within its industry group of 204 names.

The Week Ahead

Three threads merit attention next week. First, JNJ has no near-term earnings date: fiscal third-quarter results are scheduled for 13 October before the open, with estimates at $2.07 in EPS and about $25.3 billion in revenue. Second, macro data will fill the calendar, from the Richmond Fed composite index on Tuesday and EIA crude inventories on Wednesday to weekly jobless claims and the current account balance on Thursday. These may influence Treasury yields and rotation in defensive names. Third, any follow-through on the orthopaedics-unit talks and the EU regulatory path for TECVAYLI remain the main company-specific variables to watch.

In Short

JNJ closed the week up 1.66% against a mixed backdrop of clinical trial data, buyout speculation and regulatory news, outpacing the broader market. Broker positioning leans positive, with most firms rating the stock buy or overweight and the consensus target modestly above spot, yet the unusually wide target range reflects genuine disagreement over pipeline execution and any potential split of the orthopaedics business. Valuation sits around 30.9x P/E with a 1.96% dividend yield. In the latest session, large and medium orders were net buyers while small orders were net sellers. The next checkpoints are whether the DePuy Synthes discussions progress, how the TECVAYLI and other pipeline programmes advance, and how the macro yield environment shapes flows into defensive equities.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.